X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Recent Posts

PhRMA & BIO release joint principles on communications with health care professionals and payers

By Jeff Francer  |    July 27, 2016
This blog post is authored by Jeffrey Francer (PhRMA) and Deborah Shelton (BIO). We are in an era of data-driven medicine. Patients, caregivers, health care professionals and insurers want more...   Read More

PhRMA and BIO Citizen Petition to FDA calls for biosimilar labeling guidance

By Jeff Francer  |    January 21, 2016
Biosimilars will continue to become more widely available to patients in 2016 and beyond.  PhRMA supports science-based regulation of biosimilars by the Food and Drug Administration (FDA)....   Read More

Legislative and Legal Action Seeks to Improve Communications with Health Care Professionals to Better Inform Patient Care

By Jeff Francer  |    August 3, 2015
July was an active time in healthcare policy, with promising policy developments on Capitol Hill and in the court system regarding the ability of biopharmaceutical companies to share up to date...   Read More

Biopharmaceutical Industry Strongly Committed to Responsible Clinical Trial Data Sharing to Improve Public Health

By Jeff Francer  |    July 23, 2015
The biopharmaceutical industry remains committed to enhancing public health through responsible data sharing that recognizes the importance of protecting patient privacy, respects the integrity of...   Read More

Physicians Deserve Timely Authoritative Risk Information For Medicines

By Jeff Francer  |    March 11, 2015
A Washington Post article today inaccurately describes the Food and Drug Administration’s (FDA) proposed guidance on distributing peer-reviewed scientific and medical information to healthcare...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates